Summit Partners Public Asset Management LLC Sells 38,310 Shares of Establishment Labs Holdings Inc. $ESTA

Summit Partners Public Asset Management LLC cut its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 8.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 391,850 shares of the company’s stock after selling 38,310 shares during the quarter. Summit Partners Public Asset Management LLC owned 1.35% of Establishment Labs worth $28,558,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ESTA. Quarry LP bought a new position in shares of Establishment Labs during the third quarter worth approximately $34,000. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs during the fourth quarter worth approximately $47,000. Osaic Holdings Inc. increased its holdings in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the period. Truist Financial Corp bought a new position in shares of Establishment Labs during the fourth quarter worth approximately $200,000. Finally, PharVision Advisers LLC bought a new position in shares of Establishment Labs during the third quarter worth approximately $203,000. 72.91% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 330,000 shares of company stock valued at $22,854,538 in the last quarter. Company insiders own 9.99% of the company’s stock.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $82.57 on Wednesday. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -55.42 and a beta of 1.11. The firm’s 50 day simple moving average is $69.81 and its 200 day simple moving average is $69.38. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $86.00.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s revenue was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.70) EPS. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Canaccord Genuity Group raised their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Needham & Company LLC raised their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. BTIG Research raised their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Stephens increased their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.